Mayo Clinic Trial Services Closes Doors
Mayo Clinic leadership made the decision to discontinue the sales and marketing efforts of Mayo Clinic Trial Services.
Mayo Clinical Trial Services Changes
On November 5, Mayo Clinic leadership made the decision to discontinue the sales and marketing efforts of Mayo Clinic Trial Services. Effective immediately, Mayo Clinical Trial Services will no longer accept new clients or studies and will devote its activities to completing studies already started. This decision will allow Mayo to focus its efforts on its successful and growing clinical reference laboratory business, Mayo Medical Laboratories, which provides high-quality, specialized, esoteric laboratory testing services to clients throughout the world.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
